Free tool
FAERS Monitor: Arava
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020905 or its brand name (Arava, Leflunomide). Reports on generic versions are filed under their own applications.
Reports
105,017
Serious
86,607
82% of reports
Hospitalization
29,266
Death reported
9,734
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective37,556
- rheumatoid arthritis25,571
- pain20,664
- arthralgia17,585
- joint swelling16,083
- drug intolerance16,075
- fatigue15,939
- rash13,880
- off label use12,440
- abdominal discomfort12,207
- alopecia12,125
- contraindicated product administered12,068
- arthropathy11,238
- condition aggravated10,804
- swelling10,697
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,148 |
| 2005 | 1,086 |
| 2006 | 937 |
| 2007 | 1,312 |
| 2008 | 1,492 |
| 2009 | 1,511 |
| 2010 | 1,455 |
| 2011 | 1,605 |
| 2012 | 2,205 |
| 2013 | 2,685 |
| 2014 | 2,525 |
| 2015 | 3,489 |
| 2016 | 5,125 |
| 2017 | 6,990 |
| 2018 | 8,638 |
| 2019 | 10,706 |
| 2020 | 14,772 |
| 2021 | 9,336 |
| 2022 | 8,136 |
| 2023 | 5,368 |
| 2024 | 6,339 |
| 2025 | 5,339 |
| 2026 | 2,818 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,949,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contraindicated product administeredSignal | 12,068 | 132.0 | 129.1 | 945,373 |
| rheumatoid arthritisSignal | 25,571 | 57.9 | 57.2 | 1,114,440 |
| arthropathySignal | 11,238 | 50.5 | 49.5 | 436,104 |
| drug intoleranceSignal | 16,075 | 39.8 | 39.1 | 508,904 |
| joint swellingSignal | 16,083 | 30.6 | 30.2 | 401,882 |
| swellingSignal | 10,697 | 25.7 | 25.2 | 226,053 |
| abdominal discomfortSignal | 12,207 | 15.6 | 15.4 | 156,339 |
| alopeciaSignal | 12,125 | 13.1 | 12.9 | 128,487 |
| arthralgiaSignal | 17,585 | 8.8 | 8.7 | 118,783 |
| condition aggravatedSignal | 10,804 | 7.3 | 7.2 | 57,919 |
| painSignal | 20,664 | 6.9 | 6.9 | 104,513 |
| rashSignal | 13,880 | 6.6 | 6.5 | 64,583 |
| drug ineffectiveSignal | 37,556 | 5.8 | 5.8 | 156,334 |
| fatigueSignal | 15,939 | 4.2 | 4.1 | 38,991 |
| off label useSignal | 12,440 | 2.9 | 2.8 | 15,611 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.